157 related articles for article (PubMed ID: 37158934)
1. Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report.
Yoneto T; Hasumi K; Takahashi N; Seki N; Takeda Y; Yoshimoto T
J Med Case Rep; 2023 May; 17(1):190. PubMed ID: 37158934
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. [18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors.
Seifert R; Küper A; Tewes M; Heuschmid M; Welt A; Fendler WP; Herrmann K; Decker T
Oncol Res Treat; 2021; 44(7-8):400-407. PubMed ID: 34102639
[TBL] [Abstract][Full Text] [Related]
4. A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies.
Yoneto T; Hasumi K; Fujii Y; Takahashi N; Seki N; Yoshimoto T; Takeda Y
Transl Cancer Res; 2022 Oct; 11(10):3903-3911. PubMed ID: 36388043
[TBL] [Abstract][Full Text] [Related]
5. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
[TBL] [Abstract][Full Text] [Related]
6. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
[TBL] [Abstract][Full Text] [Related]
7. Immune effects of CDK4/6 inhibitors in patients with HR
Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M
EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069
[TBL] [Abstract][Full Text] [Related]
8. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
9. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
[TBL] [Abstract][Full Text] [Related]
11. Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience.
Decker T; Seifert R; Bichler M; Birtel A; Fischer G; Nonnenbroich C; Dechow T
Oncol Res Treat; 2021; 44(9):443-449. PubMed ID: 34350900
[TBL] [Abstract][Full Text] [Related]
12. Case report:
Pan B; Hao Z; Xu Y; Wang Z; Yao R; Wang X; Ren C; Zhou Y; Sun Q; Huo L
Front Oncol; 2022; 12():1095779. PubMed ID: 36620595
[TBL] [Abstract][Full Text] [Related]
13. A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
Harbeck N; Burstein HJ; Hurvitz SA; Johnston S; Vidal GA
Cancer; 2022 Jun; 128 Suppl 11():2209-2223. PubMed ID: 35536015
[TBL] [Abstract][Full Text] [Related]
14. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
17. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
18. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
19. [Locoregional recurrence of HER2-positive breast cancer - treatment after complete remission and long-term clinical benefits].
Yoshioka S; Hojo S; Toyoda Y; Noma T; Matsunaga H; Miyagaki H; Nishida H; Shingai T; Fukunaga H; Fukuzaki T; Ohigashi H; Maeura Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1924-6. PubMed ID: 25731377
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
